Printer Friendly

ICOS ANNOUNCES RESEARCH AGREEMENT WITH DOHENY EYE INSTITUTE

 ICOS ANNOUNCES RESEARCH AGREEMENT WITH DOHENY EYE INSTITUTE
 SEATTLE, June 22 /PRNewswire/ -- ICOS Corp. (NASDAQ: ICOS) announced today a research collaboration with the Doheny Eye Institute, a vision care and research institution affiliated with the University of Southern California. The new agreement covers certain novel adhesion molecules which may play important roles in a wide range of human diseases. Under the agreement, ICOS will receive exclusive worldwide rights to certain technology. In return, the Doheny Eye Institute may receive future royalties, and the princire at ICOS," said Dr. Christopher Henney, executive vice president of Research and Development. "It gives us an important leg up in what could be an important area for the development of new therapeutics." In connection with the agreement, ICOS recently filed patent applications on a new class of adhesion molecules discovered at ICOS and the Doheny Eye Institute.
 ICOS Corp. is a Seattle-based biopharmaceutical company founded to develop medications for the treatment of chronic inflammatory diseases. Primary targets of the company's drug and research development program include asthma, multiple sclerosis and rheumatoid arthritis.
 -0- 6/22/92
 /CONTACT: Janice M. LeCocq of ICOS, 206-485-1900/
 (ICOS) CO: ICOS Corp.; Doheny Eye Institute ST: Washington, California IN: MTC SU:


SC-JH -- SE001 -- 2249 06/22/92 09:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1992
Words:210
Previous Article:THE RIGHT START TO OPEN RETAIL DEPARTMENT IN RICH'S ATLANTA DEPARTMENT STORE
Next Article:GENSIA ANNOUNCES COMPLETION OF ARASINE PHASE 3 TRIAL
Topics:


Related Articles
ICOS ANNOUNCES RESEARCH AGREEMENT WITH UNIVERSITY OF UTAH
ICOS REPORTS SECOND-QUARTER RESULTS
ICOS REPORTS 1993 SECOND QUARTER RESULTS
ICOS REPORTS 1994 FIRST QUARTER RESULTS
ICOS APPOINTS HOWARD MENDELSOHN TO CHIEF ACCOUNTING OFFICER
ICOS CORP. FILES FOR RIGHTS OFFERING
ICOS CORPORATION INITIATES ENROLLMENT OF PHASE 1 STUDY
ICOS AND ABBOTT ESTABLISH COLLABORATION
Alanex and ICOS Sign Collaboration to Discover Small Molecule Drugs
Lilly and ICOS Establish a Joint Venture to Develop and Market PDE5 Compounds to Treat Sexual Dysfunction.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters